Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pepinemab and Avelumab in Metastatic Pancreatic Adenocarcinoma
NCT05102721Phase 2Active, not recruiting
- Sponsor
- Vaccinex, Inc.
- Start
- Dec 2022
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pepinemab in pancreatic adenocarcinoma (PDAC), sponsored by Vaccinex, Inc.. Started Dec 2022; status: active, not recruiting.
02
Drugs
pepinemab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05102721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05102721.